moatshark My

All holdings

Medtronic

MDT

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
4
In their latest 13F (Q3 2026)
See who
Value held
$1.8bn
Combined value at quarter end
Last quarter
2 bought
3 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q3 ’26 end
$86.29
+10.3% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-11.3%Q4 ’24
+12.5%Q1 ’25
-3.0%Q2 ’25
+9.3%Q3 ’25
+0.9%Q4 ’25
-9.8%Q1 ’26
-9.7%Q2 ’26
+10.3%Q3 ’26
Q4 ’24: -11.3%; Q1 ’25: +12.5%; Q2 ’25: -3.0%; Q3 ’25: +9.3%; Q4 ’25: +0.9%; Q1 ’26: -9.8%; Q2 ’26: -9.7%; Q3 ’26: +10.3%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

6Q4 ’23
6Q1 ’24
6Q2 ’24
6Q3 ’24
6Q4 ’24
5Q1 ’25
5Q2 ’25
5Q3 ’25
5Q4 ’25
5Q1 ’26
4Q2 ’26
1Q3 ’26
Q4 ’23: 6; Q1 ’24: 6; Q2 ’24: 6; Q3 ’24: 6; Q4 ’24: 6; Q1 ’25: 5; Q2 ’25: 5; Q3 ’25: 5; Q4 ’25: 5; Q1 ’26: 5; Q2 ’26: 4; Q3 ’26: 1

Counts the managers on this site whose 13F for that quarter includes Medtronic.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Medtronic
Matrix Asset Advisors3.0%$36.8m$36.8mTrimmed -1.6%19 qtrs
First Eagle Investment Management1.8%$1.1bn$1.1bnAdded +37%24 qtrs
Dodge & Cox0.3%$616m$616mAdded +2.4%46 qtrs
Mairs & Power0.3%$28.4m$28.4mTrimmed -9.6%47 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Medtronic
Bought or soldFiling
15 Oct 2026Martha GeoffreyChairman and CEO▼ Sold50,000$95.00$4.8mForm 4
15 Oct 2026Marinaro MichaelEVP, Pres MedSurg and Americas▼ Sold10,420$96.00$1.0mForm 4
16 Sep 2026Kiil Harry SkipEVP & President Cardiovascular▼ Sold1,483$93.65$139kForm 4

About the company

Sector
Health care · Electromedical & Electrotherapeutic Apparatus
Financial year ends
24 April
Shares outstanding
1.28bn at 28 Aug 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$17bnApr ’14
$29bnApr ’16
$30bnApr ’18
$29bnApr ’20
$32bnApr ’22
$32bnApr ’24
$36bnApr ’26
Apr ’14: $17bn; Apr ’15: $20bn; Apr ’16: $29bn; Apr ’17: $30bn; Apr ’18: $30bn; Apr ’19: $31bn; Apr ’20: $29bn; Apr ’21: $30bn; Apr ’22: $32bn; Apr ’23: $31bn; Apr ’24: $32bn; Apr ’25: $34bn; Apr ’26: $36bn
Medtronic revenue and net income by year
YearRevenueNet income
Year to Apr 2026$36bn$5k
Year to Apr 2025$34bn$5k
Year to Apr 2024$32bn$4k
Year to Apr 2023$31bn$4k
Year to Apr 2022$32bn$5k
Year to Apr 2021$30bn$3.6bn
Year to Apr 2020$29bn$4.8bn
Year to Apr 2019$31bn$4.6bn
Year to Apr 2018$30bn$3.1bn
Year to Apr 2017$30bn$4.0bn
Year to Apr 2016$29bn$3.5bn
Year to Apr 2015$20bn$2.7bn
Year to Apr 2014$17bn$3.1bn

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

Sold out last quarter

In fund portfolios

US-registered funds run by these managers that hold Medtronic, from their latest N-PORT filings.

Funds holding Medtronic
First Eagle Global FundFirst Eagle Investment Management1.0%$773m31 Jul 2026